Applied Therapeutics Inc. (APLT) - Debt to Equity

Patents for aldose reductase inhibitors and strict FDA regulations create a protected monopoly niche for Applied Therapeutics (APLT). Market price action helps track this sector, where the separate_debt_total_eq metric equals 0.00. Applied Therapeutics (APLT) focuses on therapies for diabetic complications and rare metabolic pathologies, planning revenue from the commercialization of new drugs. Meanwhile, small molecule development is conducted in New York, while drug manufacturing is delegated to external contractors.

Investors are assessing the stability of Applied Therapeutics (APLT) through the total liabilities-to-equity ratio, which determines the business's degree of dependence on external financing and its solvency. Analyzing the debt-to-equity trend confirms that low leverage, combined with the future monopolization of the rare disease therapy market, creates a solid financial foundation for the global scaling of commercial operations.